Form 4: CFO Kevin Green Boosts CERUS Stake with RSU Grant

CERUS Corp's Chief Financial Officer, Kevin Green, was granted 300,000 Restricted Stock Units, increasing his beneficial ownership.

Summary

• Kevin Dennis Green, Chief Financial Officer of CERUS CORP, acquired 300,000 shares of common stock through a Restricted Stock Unit (RSU) grant.
• The RSUs vest in two annual installments: 34% of the grant vests on March 12, 2027, and 66% vests on March 12, 2028, subject to continuous service.
• Following this transaction, Green beneficially owns a total of 1,187,262 shares.
• This total includes 5,837 shares purchased on August 29, 2025, and 5,558 shares purchased on February 27, 2026, under the Issuer's Employee Stock Purchase Plan.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal, indicating executive retention and alignment of interests, which is generally favorable for investor confidence.

Positives

• CFO Kevin Green received a significant grant of 300,000 Restricted Stock Units, aligning his interests with shareholders.
• The vesting schedule encourages long-term commitment from a key executive through March 2028.
• Increased beneficial ownership by a key executive can signal confidence in the company's future prospects.

Future Outlook

The RSU vesting schedule indicates a commitment from the CFO to the company's performance through March 2028, aligning executive incentives with long-term company success.

Industry Context

StockSavvy.ai notes that RSU grants are a common form of executive compensation in the biotechnology and medical device industries, aiming to align executive incentives with long-term shareholder value creation. This grant to a CFO is standard practice for retaining key financial leadership.

Comparison to Industry Standards

• The grant of 300,000 RSUs to a Chief Financial Officer is a substantial award, comparable to grants seen in mid-to-large cap biotechnology companies for key executives.
• Vesting schedules over two to three years are typical for RSU grants in the industry, promoting executive retention and long-term focus.
• Companies like Gilead Sciences or Amgen often use similar equity compensation structures for their executive teams to incentivize performance and align with shareholder interests.

Stakeholder Impact

• Shareholders: Potentially positive, as executive compensation tied to equity can align management's interests with shareholder value creation.
• Employees: May signal stability in executive leadership and a commitment to long-term company goals.

Next Steps

• First RSU vesting on March 12, 2027 (34% of grant).
• Second RSU vesting on March 12, 2028 (66% of grant).

Key Dates

Recommendation

This Form 4 filing reports a routine executive compensation event (RSU grant) and an increase in beneficial ownership. While positive for executive alignment, it does not present new fundamental information that would warrant a change in investment recommendation. It reinforces a 'hold' stance for investors already in CERS, as it's a standard operational disclosure.

Keywords

CERUS CORP, CERS, Form 4, Insider Trading, Restricted Stock Units, RSU, Executive Compensation, Kevin Green, CFO, Stock Grant, Beneficial Ownership